Biometric Data vs Questionnaires: Why Real Data Wins in Underwriting

The debate over biometric data vs questionnaires in underwriting is no longer theoretical. As carriers expand accelerated and instant-issue pathways that eliminate paramedical exams, the quality of remaining data inputs becomes the primary determinant of underwriting accuracy. Self-reported questionnaires--the backbone of simplified underwriting for decades--carry well-documented accuracy limitations that create measurable adverse selection exposure. Objective biometric data, captured through technologies like remote photoplethysmography and wearable sensors, offers a fundamentally different evidence base. For chief underwriting officers, actuaries, and reinsurers, the question is no longer whether biometric data is superior to self-report--the research is clear on that point--but how to operationalize the transition at scale.

Over 7% of life insurance policies written contain some form of non- or under-disclosure, leading to approximately 17% of claims filed being affected--representing an estimated $15 billion in annual claims costs, according to industry nondisclosure research.

The Self-Report Problem: Quantifying the Gap

The insurance industry has long understood that applicants misrepresent health information. What has changed is the scale of the problem in a world where fluid verification is disappearing.

Tobacco misrepresentation is the most extensively documented category. In 2021, over 43% of individuals testing positive for cotinine--a nicotine metabolite--denied tobacco use at the time of application. CRL Corp estimates the resulting mortality cost to the life insurance industry at $4 billion annually. The trajectory is worsening: tobacco nondisclosure rates rose from 2.0% of the applicant population in 2015 to 3.5% in 2022, coinciding with the industry's shift toward fluidless underwriting.

Medical misrepresentation extends well beyond tobacco. Munich Re's survey of life insurers ranked medical misrepresentation as the single largest fraud concern, averaging 4.0 on a 5-point severity scale. The survey also documented increasing material misrepresentation related to cancer history and infectious respiratory diseases in fully underwritten cases over the preceding five years.

Behavioral and lifestyle nondisclosure compounds the problem. Research on self-reported health data consistently demonstrates that individuals underreport risky behaviors and overreport healthy ones. This is not always intentional fraud--cognitive bias, poor recall, and social desirability effects all contribute to systematic inaccuracy in questionnaire responses.

The cumulative effect is a widening gap between the risk profile that questionnaires describe and the actual mortality risk that carriers bear--particularly in accelerated and instant-issue channels where no objective verification backstop exists.

What Biometric Data Actually Captures

Biometric data in the underwriting context refers to objective physiological measurements that reflect an individual's health status independent of self-report. The key categories relevant to life insurance risk assessment include:

Cardiovascular signals. Heart rate, heart rate variability (HRV), and blood pressure are among the strongest individual predictors of cardiovascular and all-cause mortality. The UK Biobank study--a collaboration between RGA and the University of Leicester analyzing 407,569 participants--found that resting heart rate was among the non-traditional factors that "dramatically improved the ability to differentiate mortality and morbidity risks." A PLOS One study using UK Biobank data further documented age-, sex-, and disease-specific associations between resting heart rate and cardiovascular mortality.

Respiratory markers. Respiratory rate and breathing patterns provide signals relevant to pulmonary health, stress states, and overall physiological fitness. Hospital-based validation studies published in PMC confirmed that remote photoplethysmography (rPPG) achieves excellent agreement with clinical respiratory rate measurement across a 6-48 cycles-per-minute range using Bland-Altman analysis.

Metabolic and behavioral indicators. While not directly measurable through rPPG, wearable device data captures physical activity levels, sleep duration and quality, and longitudinal trends in these behaviors--all of which carry actuarial significance. The UK Biobank research specifically examined walking pace and grip strength as mortality predictors with positive results.

Biometric Data vs Questionnaires: Head-to-Head Comparison

Evaluation Criterion	Self-Reported Questionnaire	Objective Biometric Data
Accuracy	Subject to misrepresentation, recall bias, social desirability effects	Measured directly from physiological signals; not subject to applicant manipulation
Tobacco detection	43%+ of cotinine-positive applicants deny use	Heart rate, HRV patterns provide corroborative cardiovascular signals
Mortality prediction	Limited discriminatory power beyond broad risk categories	Individual biomarkers improve mortality prediction vs. self-reports (PMC, 2014)
Longitudinal signal	Single-point-in-time snapshot with no verification	Wearables provide continuous data; rPPG enables periodic reassessment
Fraud resistance	High exposure--7%+ nondisclosure rate on policies written	Low exposure--physiological signals are difficult to fabricate
Applicant friction	Low (form completion)	Low-to-moderate (30-60 second camera scan or wearable sync)
Regulatory maturity	Well-established; decades of precedent	Evolving; NAIC Model Bulletin and state-level biometric privacy laws apply
Cost per assessment	Minimal	Low for rPPG; moderate for wearable integration
Scalability	High	High for rPPG (smartphone-based); moderate for wearable pathways

Industry Applications: The Operational Shift

For Chief Underwriting Officers: Closing the Verification Gap

The core CUO challenge in 2026 is that accelerated underwriting removed the paramedical exam without replacing it with an equivalently objective data source. Questionnaires remain in the workflow, but their role has shifted from supplementary (backed by labs) to primary (standing alone). This is an untenable position from a risk management perspective.

Biometric data offers a pragmatic middle path: objective measurement without the friction, cost, and cycle-time penalty of traditional exams. Gen Re's 2024 survey found that the average accelerated underwriting workflow reduces cycle time by 18 business days versus full underwriting. The key is ensuring that this speed gain does not come at the cost of risk selection quality--and biometric data is the most scalable tool available to maintain that balance.

For Actuarial Teams: Recalibrating Mortality Assumptions

The actuarial implications of the questionnaire-to-biometric shift are significant. Mortality tables developed from fluid-verified populations embed an assumption of data accuracy that does not hold for self-reported cohorts.

Research published in PMC (2014) directly addressed this gap, finding that "a summary measure of biomarkers improves mortality prediction compared with self-reports alone." The study further demonstrated that individual biomarkers outperform composite biomarker scores, and that tracking biomarker changes over time yields additional predictive improvement. For actuaries, this means that even partial biometric data--a resting heart rate captured at application, for example--has the potential to improve pricing accuracy for accelerated and instant-issue business.

Munich Re's Biometric Portfolio Analysis, drawing on 15+ years of data from more than 30 participating insurers, provides an emerging industry benchmark for understanding how biometric factors interact with traditional rating variables. Their multivariate and machine learning analyses are enabling actuaries to "gain deep insights into their own datasets and derive new actuarial findings."

For Reinsurers: Differentiating Treaty Quality

Reinsurers increasingly need to distinguish between accelerated underwriting programs based on the quality of their data inputs. A carrier using only questionnaires and prescription databases presents a different risk profile than one incorporating real-time biometric measurement.

Swiss Re's Assessment Engine--with its 2,322 individual risk factors and 30,000+ rules--represents the kind of granular differentiation framework that enables risk-appropriate treaty pricing. As biometric data becomes a standard input, reinsurers that can quantify its impact on mortality experience will hold a pricing advantage.

The Research Verdict: Objective Measurement Outperforms Self-Report

The evidence base supporting biometric data over questionnaires is multi-dimensional:

• PMC (2014) -- Biomarkers as mortality predictors. A landmark study demonstrated that biomarkers improve mortality prediction beyond self-reports. The finding that individual biomarkers outperform composite scores suggests that even a small number of well-chosen physiological measurements can materially improve risk discrimination.

• UK Biobank -- RGA/University of Leicester. Analysis of 407,569 participants found that non-traditional biometric factors including resting heart rate significantly enhanced mortality and morbidity risk differentiation when layered onto traditional underwriting variables. Results published in Mayo Clinic Proceedings.

• Journal of Insurance Medicine (2013) -- Lab predictors of cancer mortality. Demonstrated that biometric measurements (liver function tests, cholesterol, blood pressure) were independently predictive of cancer mortality in insured populations, reinforcing the actuarial value of objective physiological data.

• Frontiers in Digital Health (2025) -- rPPG technology review. Comprehensive review documenting well-established health outputs from smartphone-based rPPG: heart rate, respiratory rate, HRV, hypertension risk, and stress detection. The review noted growing research interest, with 81.4% of cited bibliography published between 2015 and 2025.

• Munich Re fraud survey. Medical misrepresentation ranked as insurers' top fraud concern (4.0/5.0 severity). Material misrepresentation rates of 4-6 per 1,000 applications represent uninsurable risks that questionnaires alone cannot detect.

What the Future Looks Like

The transition from questionnaire-dependent to biometric-informed underwriting will not happen overnight, but the trajectory is unmistakable:

Near-term (2026-2027). Carriers will integrate rPPG and wearable data as supplementary signals within existing accelerated underwriting frameworks. These signals will initially serve as risk flags rather than primary decisioning variables, allowing actuarial teams to build experience data before adjusting pricing.

Medium-term (2027-2029). As biometric experience data accumulates, carriers and reinsurers will begin to price biometric-verified business differently from questionnaire-only business. Expect treaty structures that reward objective data quality with more favorable reinsurance terms.

Long-term (2029+). Biometric data will transition from supplementary to primary, with questionnaires reduced to a consent and disclosure mechanism rather than a risk assessment tool. The NAIC's regulatory framework will need to evolve in parallel, particularly around biometric data privacy and algorithmic fairness.

The regulatory infrastructure is already forming. The NAIC's AI Model Bulletin, adopted by 23 states and Washington, D.C. by late 2025, provides baseline governance for algorithmic underwriting. State-level biometric privacy laws add a data-handling dimension. Carriers that build compliant biometric data pipelines now will be positioned to lead as the market transitions.

Frequently Asked Questions

Can biometric data fully replace questionnaires in underwriting?

Not yet, and not in the near term. Questionnaires capture information that biometric sensors cannot--family history, occupation, avocations, travel history, and other disclosure-dependent variables. The value proposition of biometric data is not replacement but augmentation: adding an objective verification layer that compensates for the well-documented limitations of self-report. Over time, as biometric technology matures and experience data accumulates, the relative weight of questionnaire data in the underwriting algorithm will likely decrease.

What is the biggest risk of relying on questionnaires alone?

Adverse selection driven by systematic misrepresentation. Industry data shows 7%+ nondisclosure rates on written policies, tobacco misrepresentation affecting 43%+ of cotinine-positive applicants, and $15 billion in annual claims costs attributable to under-disclosure. Without an objective data source, carriers in accelerated and instant-issue channels have limited ability to detect or correct for these inaccuracies at the point of underwriting.

How do carriers validate that biometric data improves underwriting outcomes?

Validation requires retrospective mortality and morbidity analysis comparing cohorts underwritten with and without biometric inputs. Munich Re's Biometric Portfolio Analysis provides an industry-scale framework for this comparison, drawing on 15+ years of data. Individual carriers can also conduct internal A/B analyses, tracking claims experience across underwriting pathways. The key metric is whether biometric-informed cohorts demonstrate mortality ratios closer to fully underwritten expectations than questionnaire-only cohorts.

Are there fairness concerns with using biometric data in underwriting?

Yes, and they require careful management. Biometric signals can vary with age, sex, ethnicity, and medical conditions in ways that could introduce unintended discrimination if not properly controlled. However, objective physiological measurement may actually reduce certain forms of bias present in self-reported data--where socioeconomic factors, health literacy, and cultural norms influence how individuals respond to questionnaires. The NAIC's regulatory guidance requires carriers to demonstrate that AI-driven underwriting decisions, including those informed by biometric data, are non-discriminatory and explainable.

---

The evidence is unambiguous: objective biometric data outperforms self-reported questionnaires across every dimension that matters to underwriting--accuracy, fraud resistance, mortality prediction, and scalability. The carriers that integrate real physiological measurement into their underwriting pipelines will price risk more accurately and write more profitable business. For teams evaluating how biometric health intelligence fits into their risk assessment strategy, learn how health-scan technology is reshaping underwriting data quality.